Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Antimicrobial properties found in scorpion venom
The study highlights the potential for other healing compounds to be identified in the toxins of scorpions, snakes, snails and other creatures. (Stock photo)
Compounds kill staph and drug-resistant TB bacteria - study

Scientists have discovered two healing compounds in scorpion venom that can kill staphylococcus and drug-resistant TB bacteria.

The scorpion, Diplocentrus melici (not pictured), is native to eastern Mexico and can only be found in the rainy season - it is buried during the winter and dry seasons. When researchers milked its venom, they noticed they it changed from clear to brownish in colour when exposed to the air.

Two chemical compounds were found to be responsible for the colour change, one of which turned red when exposed to air, the other blue. The compounds are two previously unknown benzoquinones, a class of ring-like molecules known to have antimicrobial properties.

Through much trial and error, the team - which comprised researchers from Stanford and Mexico - managed to synthesise the compounds. The red benzoquinone was particularly effective at killing staphylococcus bacteria, while the blue one was lethal to both normal and multi-drug-resistant strains of TB-causing bacteria.

Researchers said being able to synthesise the venom is highly important, as the amount of venom components that can be obtained from animals is extremely low.

The team are planning to work together in determining why the compounds are present in the venom and whether they can be transformed into drugs. Their findings have been published in the journal Proceedings of the National Academy of Sciences.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.